Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 09, 2024

BUY
$0.62 - $1.0 $16 - $26
26 Added 9.7%
294 $0
Q3 2023

Nov 13, 2023

BUY
$0.47 - $0.9 $9 - $18
21 Added 8.5%
268 $0
Q2 2023

Aug 15, 2023

BUY
$0.38 - $1.09 $22 - $65
60 Added 32.09%
247 $0
Q1 2023

May 12, 2023

BUY
$0.42 - $0.75 $0 - $1
2 Added 1.08%
187 $0
Q4 2022

Feb 13, 2023

BUY
$0.54 - $9.8 $2 - $49
5 Added 2.78%
185 $0
Q3 2022

Nov 14, 2022

BUY
$0.13 - $12.4 $1 - $161
13 Added 7.78%
180 $0
Q2 2022

Aug 12, 2022

BUY
$1.11 - $3.46 $185 - $577
167 New
167 $0

Others Institutions Holding SABS

About SAB Biotherapeutics, Inc.


  • Ticker SABS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,030,900
  • Market Cap $184M
  • Description
  • SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases ...
More about SABS
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.